Biopharma takeouts in the $1-5bn range jumped in 2021, as rising valuations made their mark.
Small and mid-sized developers upped deal-making activity last year, a deep dive into M&A data finds.
Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
Like Aduhelm this long-discontinued amyloid beta MAb reduced brain beta amyloid; so have several other industry projects.
And Royalty Pharma has paid a king’s ransom.
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
The company has spent five years buying in discontinued projects, and at last has managed to sell one of these on at a nice profit.
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.